Asia tech stocks slide tracking Wall St losses amid AI doubts, govt. uncertainty
Rachel E. Haurwitz, the President and CEO of Caribou Biosciences , Inc. (NASDAQ:CRBU), recently acquired 20,000 shares of the company’s common stock. The purchase comes as the stock trades near its 52-week low, having declined over 80% in the past year. According to InvestingPro analysis, the company appears undervalued at its current market capitalization of $94 million. The shares were purchased on March 14, 2025, at a weighted average price of $1.02 per share, totaling approximately $20,400. This transaction was executed through multiple trades at prices ranging from $1.00 to $1.03 per share. The shares are held by The City Canyon Family Trust, where Haurwitz is a co-trustee with her spouse. Following this transaction, Haurwitz’s direct ownership stands at 295,450 shares, while indirect ownership by trust amounts to 3,369,395 shares. Want deeper insights into insider trading patterns and comprehensive valuation metrics? Unlock exclusive analysis with InvestingPro, featuring 14+ additional ProTips and detailed financial health scores.
In other recent news, Caribou Biosciences reported a narrower-than-expected loss for the fourth quarter of 2024, posting a loss of $0.39 per share compared to analyst estimates of a $0.42 per share loss. The company’s revenue for the quarter was $2.08 million, slightly below the consensus estimate of $2.12 million and a decrease from $3.6 million in the same quarter the previous year. Caribou ended 2024 with $249.4 million in cash, cash equivalents, and marketable securities, which it expects will support operations into the second half of 2026. The company is advancing four clinical programs targeting hematologic malignancies and autoimmune diseases, with key clinical data readouts anticipated in the first half of 2025. These include results from the ANTLER Phase 1 trial of CB-010 in second-line large B cell lymphoma and initial data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. For the full year 2024, Caribou reported a net loss of $149.1 million, which was wider than the $102.1 million loss in 2023, primarily due to increased research and development expenses.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.